---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-25-000024"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T01:55:26.324299+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

## Summary
- Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).
- Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.
- R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.
- Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney.

## SEC filing metadata
- accession: 0001082554-25-000024
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/0001082554-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/uthr-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-25-000024
- JSON: https://secwatch.observer/filing/0001082554-25-000024.json
- Plain text: https://secwatch.observer/filing/0001082554-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.